Läs upp

Cookies

Den här webbplatsen använder så kallade cookies. Cookies är små textfiler som lagras i din dator och sparar information om olika val som du gjort på en webbsida – t ex språk, version och statistik – för att du inte ska behöva göra dessa val en gång till. Tekniken är etablerad sedan många år tillbaka och används idag på väldigt många webbplatser på Internet.

Du kan när som helst ändra cookieinställningarna för denna webbplats.

FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt och länkar

Sök apotek med läkemedlet i lager

Sök lagerstatus

Tarceva

MiljöinformationReceptstatusFörmånsstatus
Roche

Filmdragerad tablett 25 mg
(Vit till gulaktig, rund, bikonvex filmdragerad tablett med "T 25" ingraverat på ena sidan.)

EGFR-tyrosinkinashämmare

Aktiv substans:
ATC-kod: L01XE03
Läkemedel från Roche omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?

Miljöpåverkan (Läs mer om miljöpåverkan)

Erlotinib

Miljörisk: Användning av erlotinib har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Erlotinib är potentiellt persistent.
Bioackumulering: Erlotinib har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Identification and characterisation

Chemical name: Erlotinib hydrochloride

CAS number: 183319-69-9 [1]

Molecular weight: 429.9 [1]

Remark: -

Brand name: Tarceva [1]


Physico-chemical properties

Aqueous solubility 810 mg/l [1]

Dissociation constant, pKa 5.7 (base) [1]

Melting point 228–238 °C, with partial decomposition [1]

Vapour pressure 7.9*E–09 Pa QSAR

Boiling point ND

KH 2.1*E-06 – 8.6*E-11 atm*m3/mol QSAR

QSAR = QSAR-modelled (EPISuite, SPARC, ACD Solaris)


Predicted Environmental Concentration (PEC)

PEC is calculated according to the formula:

PEC (μg/L) = (A x 1'000'000'000 x (100-R)) / (365 x P x V x D x 100) = 1.5 x 10-6 x A x (100 - R) = 0.00133 μg/L


Where:

A Sold quantity = 8.88261 kg/y (total sold amout API in Sweden year 2017, data from IQVIA)

R Removal rate = 0 % Default [2]

P Population of Sweden = 9000000

V Volume of Wastewater = 200 l/day Default [2]

D Factor for Dilution = 10 Default [2]


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Green alga (Pseudokirchneriella subcapitata): [3]

ErC50 72 h (growth rate) >100 mg/l nominal concentration (OECD 201)

EbC50 72 h (biomass) >100 mg/l nominal concentration (OECD 201)

NOEC 72 h = 1.39 mg/l (OECD 201)


Water-flea (Daphnia magna): [4]

EC50 48 h (immobilisation) >100 mg/l (OECD 202)

NOEC 48 h (immobilisation) = 0.7 mg/l (OECD 202)


Water-flea (Daphnia magna): [5]

21 d NOEC (overall) = 0.6 mg/l (OECD 211)


Zebra fish (Danio rerio): [6]

LC50 96 h (mortality) >100 mg/l (OECD 203)

NOEC 96 h (mortality) = 100 mg/l (OECD 203)


Zebra fish (Danio rerio): [7]

36 d NOEC (mortality) = 0.56 mg/l (OECD 210)


Micro-organisms (activated sludge):

3 h NOEC = 1000 mg/l (OECD 209) [8]


PNEC Derivation

The PNEC is based on the following data:

PNEC (mg/l) = lowest chronic NOEC/10, where 10 is the assessment factor used. A NOEC of 560 μg/l in the fish early life stage test has been used for this calculation.

PNEC = 560 / 10 = 56 μg/l


Environmental Risk Classification (PEC/PNEC Ratio)

PEC Predicted Environmental Concentration = 0.00133 μg/L

PNEC Predicted No Effect Concentration = 56 μg/L

Ratio PEC/PNEC = 0.000024


PEC/PNEC =0.00133/56 = 0.000024 for Erlotinib hydrochloride which justifies the phrase 'Use of Erlotinib hydrochloride has been considered to result in insignificant environmental risk.'


Degradation


Biotic Degradation

Ready biodegradability: [9]

0% after 28 days of incubation BOD/ThOD (OECD 301 C)


Inherent biodegradability: [10]

0% after 28 days of incubation BOD/ThOD (OECD 302 C)


Other degradation information: [11]

DT50 (water) = <2 d (OECD 308)

DT50 (total system) = 26–86 d (OECD 308)


Abiotic Degradation

Photodegradation: stable drug stability testing [1]

Hydrolysis: stable drug stability testing [1]


Erlotinib hydrochloride is not readily biodegradable; it is also not degradable in water/sediment systems. This justifies the phrase 'Erlotinib hydrochloride is potentially persistent.'


Bioaccumulation/Adsorption

logPOW = 2.98-3.53 (pH 4.9–6.5, 20 °C) (OECD 107) [12]

KOC (sediment) = 5693 l/kg (OECD 308 / OECD 301 C with artificial sediment) [11]

BCF = 7.8–10.1 l/kg (OECD 305) [13]


Erlotinib hydrochloride has low potential for bioaccumulation.


Excretion/metabolism

Erlotinib is mainly Phase-I-metabolised by hepatic cytochrome -P450 enzymes CYP3A4 and, to a lesser extent, CYP1A2 as well as by pulmonary CYP1A1. Excretion of Erlotinib and its metabolites in man is mainly (≥90%) by faecal and secondarily by urinary pathway. The median half-life of elimination on repeated once-daily administration in patients is approximately 36 hours. [14]


PBT/vPvB Assessment


P: Freshwater half-life <2 d [11]

Sediment half-life 86 y [11]

Persistence criteria fulfilled? Potentially P


B: BCF (experimental) 10.1 [13]

alternatively, base or acid?

alternatively, logDOW(p H 7)

Bioaccumulation criteria fulfilled? no significant bioaccumulation (BCF < 2000)


T: chronic NOEC < 0.01 mg/l? n not T [4][6]

CMR substance? n not CMR [1]

Endocrine-disrupting effects? n not ED

T criteria fulfilled? not T


PBT Assessment: not PBT


References

1. F. Hoffmann-La Roche Ltd. 2019. Safety Data Sheet for Tarceva, 05.03.2019; https://www.roche.com/sustainability/what_we_do/for_communities_and_environment/environment/safety_data_sheetsrow. htm

2. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment. http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm

3. Study Report: Solvias study no. L01-009453: Toxicity of Ro 50-8231/001 to Green Algae (Growth Inhibition Test), May 2002.

4. Study Report: Solvias study no. L01-009454: Acute Toxicity of Ro 50-8231/001 to Daphnia magna (Immobilisation Test), May 2002-

5. Study Report: ibacon study no. 39571221: Influence of Tarceva (Erlotinib) to Daphnia magna in a Reproduction Test, October 2008.

6. Study Report: Solvias study no. L01-009456: Acute Toxicity of Ro 50-8231/001 to Zebrafish (Danio rerio) under Semi-Static Conditions, May 2002.

7. Study Report: ibacon study no. 39573232: Toxicity of Tarceva (Erlotinib) to Zebrafish (Danio rerio ) in an Early-Life Stage Test, December 2008.

8. Study Report: RCC study no. A15996: Tarceva: toxicity to activated sludge in a respiration inhibition test, November 2005.

9. Study Report: SPL study no. 1384/019: OSI-774-01: Assessment of ready biodegradability in the Modified MITI Test (I), May 2003.

10. F. Hoffmann-La Roche Ltd. Tarceva – Oekotoxikologische Beurteilung Nr. E-03/01, June 2003.

11. Study Report: RCC study no. A15243: [14C]-Tarceva: Route and Rate of Degradation in Aerobic Aquatic Sediment Systems, June 2006.

12. Study Report: SPL study no. 1384/018: OSI-774-01: Determination of partition coefficient, September 2002.

13. Study Report: RCC study no. A13061: Flow-through Fish Test with [14C]-Tarceva in Rainbow Trout (Oncorhynchus mykiss), May 2006.

14. F. Hoffmann-La Roche Ltd. Erlotinib: Environmental Risk Assessment Summary, April 2018. https://www.roche.com/sustainability/environment/environmental-risk assessment-downloads.htm


Välj läkemedelstext
Hitta direkt i texten
Av